DUBLIN, Aug. 06, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/qdncmb/investigation) has announced the addition of the "Investigation Report on China's Glucosamine Market, 2010-2019" report to their offering.
Osteoarthritis (OA) is a chronic degenerative disease, and it is also the commonest arthritis in the clinic. The lesion is a slow yet progressing process. Major symptoms include wearing away and damage of articular cartilage, whereas clinical symptoms include arthralgia, swelling of joint, joint deformity and limited mobility. The elderly are at high risk of osteoarthritis. About 70-90% of old people aged above 75 suffer from osteoarthritis.
Common therapeutic medicines used for the treatment of osteoarthritis include analgesic and non-steroidal anti-inflammatory drugs (NSAID) which howeverwill initiate serious adverse reactions in gastrointestinal tract and cardiovascular system, particularly during long-term use. The optimal therapeutic medicine is disease modifying antirheumatic drug (DMARD) that can both alleviate arthralgia and delay the damaging process of joint structure. In the past ten years, chondroitin, an ingredient of cartilage, and glucosamine have been increasingly put into use around the world.
As a kind of natural monosaccharide, glucosamine is an ingredient of cartilage matrix and bone fluid. Glucosamine can complement ectogenous glucosaminoglycan, provide the precursor of disaccharide unit needed in the synthsis of glycosaminoglycan inside the body, and stimulate synthesis of proteoglycan and collagen in the chondrocyte, as well as complement lost ingredients of cartilage matrix and inhibit the expression of matrix metalloproteinase so as to maintain the normal metabolism of cartilage matrix and accelerate the recovery of cartilage. Besides, glucosamine can alleviate damage to cartilage by removing free radical and give play to the anti-flammable effect. Currently, glucosamine is still the most popular nutrition drug for joints and cartilages in the U.S. In Europe, it is managed as a prescription drug.
Glucosamine has been growing at a rapid pace after entering the Chinese market, with its annual sales value rising from CNY 42 million in 2005 to CNY 400 million in 2014 and its CAGR during the period of 2005-2014 reaching up to 28.46%. Glucosamine is of great demand in China. Most of the market share has been occupied by Shanxi Zhongyuanwei Pharmaceutical Co., Ltd, Bright Future Pharmaceutical Laboratories Limited, Rottapharm Ltd, Zhejiang Hisun Pharmaceutical Co., Ltd and Jiangsu Qing Jiang Pharmaceutical Co., Ltd, among which Shanxi Zhongyuanwei Pharmaceutical Co., Ltd owns the largest market share, with its market share for sales value in 2014 reaching 27.5%.
For more information visit http://www.researchandmarkets.com/research/qdncmb/investigation
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets